Moderna Stock News

In a time when AI is a friend and a guide through complex financial markets, AI-driven insights provide delight and optimism. Let us begin a deep dive into how ChatGPT, a sophisticated AI model, can g

Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discover

Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.

Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its

In the most recent trading session, Moderna (MRNA) closed at $99.30, indicating a -0.73% shift from the previous trading day.

Metagenomi Technologies, a genetic medicines company backed by Moderna , said on Monday it was targeting a valuation of up to $638 million for its initial public offering in New York.

CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to repo

Moderna's shares have plunged with declining demand for its COVID-19 vaccine. Several analysts have renewed optimism about the biotech stock as it expands beyond COVID.

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

The broad-based S&P 500 has been Wall Street's top "health" barometer for decades. High-water price targets from a trio of Wall Street analysts imply triple-digit gains to come for three S&P 500 compo

In the latest trading session, Moderna (MRNA) closed at $101.11, marking a -0.79% move from the previous day.

Moderna's revenue and earnings dropped off a cliff last year. However, the biotech is close to launching a new product.

Pfizer is completing its biggest string of product launches ever, which should spur a new era of growth. Moderna expects to soon have a new RSV vaccine on the market, with other products to follow.

Moderna went from being a stock market winner, soaring more than 400%, to a losing stock in recent times. Investors have worried about coronavirus vaccine declines and the biotech company's future rev